Glomerular disease

Amyloidosis and fibrillary glomerulonephritis

• Diagnosis of primary (AL) amyloidosis
• Fibronectin glomerulopathy
• Glomerular diseases due to nonamyloid fibrillar deposits
• Pathogenesis and clinical features of AL (primary) amyloidosis and light and heavy chain deposition diseases
• Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases
• Renal amyloidosis
• Treatment of secondary (AA) amyloidosis

Diabetic nephropathy

• Aldose reductase inhibitors in the prevention of diabetic complications
• Glycemic control and vascular complications in type 1 diabetes mellitus
• Mechanisms of glomerular hyperfiltration in diabetes mellitus
• Microalbuminuria and cardiovascular disease
• Microalbuminuria in type 1 diabetes mellitus
• Microalbuminuria in type 2 diabetes mellitus
• Overview of diabetic nephropathy
• Protein kinase C and the vascular complications of diabetes mellitus
• Treatment of diabetic nephropathy

Focal segmental glomerulosclerosis

• Collapsing focal segmental glomerulosclerosis and other renal diseases associated with HIV infection
• Collapsing focal segmental glomerulosclerosis not associated with HIV infection
• Focal segmental glomerulosclerosis: Recurrence after transplantation
• Pathogenesis and diagnosis of focal segmental glomerulosclerosis
• Treatment of primary focal segmental glomerulosclerosis

Hematuria

• Evaluation of hematuria in adults
• Exercise-induced hematuria
• Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy
• Hematuria: Glomerular versus extraglomerular bleeding
• Red to brown urine: Hematuria; hemoglobinuria; myoglobinuria
• Thin basement membrane nephropathy (benign familial hematuria)

Hereditary nephritis

• Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)
• Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy
• Thin basement membrane nephropathy (benign familial hematuria)

IgA nephropathy

• Clinical presentation and diagnosis of IgA nephropathy
• Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy
• IgA nephropathy: Recurrence after transplantation
• Pathogenesis of IgA nephropathy
• Renal manifestations of Henoch-Schönlein purpura
• Treatment and prognosis of IgA nephropathy

Infection and glomerular disease

• Hematuria following respiratory infection
• Poststreptococcal glomerulonephritis
• Renal disease associated with hepatitis B virus infection
• Renal disease associated with hepatitis C virus infection
• Renal disease in infective endocarditis
• Schistosomiasis and glomerular disease

Lupus nephritis

• Clinical features and therapy of membranous lupus nephritis
• Clinical trials of immunosuppressive therapy in proliferative lupus nephritis
• Drug-induced lupus
• End-stage renal disease due to lupus nephritis
• Indications for renal biopsy in patients with lupus nephritis
• Therapy of diffuse or focal proliferative lupus nephritis
• Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis
• Types of renal disease in systemic lupus erythematosus

 
Membranoproliferative glomerulonephritis

• Classification and causes of membranoproliferative glomerulonephritis
• Membranoproliferative glomerulonephritis type II (dense deposit disease)
• Membranoproliferative glomerulonephritis: Recurrence after transplantation
• Treatment of membranoproliferative glomerulonephritis type I and type III

Membranous nephropathy

• Alternative agents in the treatment of idiopathic membranous nephropathy
• Causes and diagnosis of membranous nephropathy
• Clinical trials of initial immunosuppressive therapy in idiopathic membranous nephropathy
• Membranous nephropathy and renal transplantation
• Renal disease in patients with rheumatoid arthritis
• Renal disease with penicillamine
• Treatment of idiopathic membranous nephropathy

Minimal change disease

• Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome
• Diagnosis and causes of minimal change disease in adults
• Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy
• Treatment of minimal change disease in adults

Nephrotic syndrome and proteinuria

• Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome
• Biology of glomerular podocytes
• Endocrine dysfunction in the nephrotic syndrome
• Evaluation of isolated proteinuria in adults
• Lipid abnormalities in nephrotic syndrome
• Measurement of urinary protein excretion
• Mechanism and treatment of edema in nephrotic syndrome
• NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome
• Orthostatic or postural proteinuria
• Overview of heavy proteinuria and the nephrotic syndrome
• Patient information: Split urine collection for orthostatic proteinuria
• Renal vein thrombosis and hypercoagulable state in nephrotic syndrome
• Serologic tests in the evaluation of nephrotic syndrome
• Significance of lipiduria

Vasculitis

• Alternative agents in the treatment of Wegener's granulomatosis and microscopic polyangiitis
• Clinical manifestations and diagnosis of polyarteritis nodosa
• Clinical spectrum of antineutrophil cytoplasmic antibodies
• General principles of the use of cyclophosphamide in rheumatic and renal disease
• Hypersensitivity vasculitis in adults
• Initial immunosuppressive therapy in Wegener's granulomatosis and microscopic polyangiitis
• Maintenance immunosuppressive therapy in Wegener's granulomatosis and microscopic polyangiitis
• Pathogenesis of Wegener's granulomatosis and related vasculitides
• Patient and renal outcomes in Wegener's granulomatosis and microscopic polyangiitis
• Relapsing disease in Wegener's granulomatosis and microscopic polyangiitis
• Renal manifestations of Henoch-Schönlein purpura
• Renal manifestations of systemic vasculitis
• Treatment and prognosis of polyarteritis nodosa
• Treatment of cyclophosphamide-resistant Wegener's granulomatosis and microscopic polyangiitis

Other

• Acute glomerulonephritis and pulmonary hemorrhage
• Antiphospholipid syndrome and the kidney
• Clinical manifestations and diagnosis of essential mixed cryoglobulinemia
• Differential diagnosis of glomerular disease
• Hypocomplementemia in glomerular disease
• Indications for and complications of renal biopsy
• Lipoprotein glomerulopathy
• Mechanisms of immune injury of the glomerulus
• Pathogenesis of tissue injury in glomerulonephritis
• Renal disease in infective endocarditis
• Renal disease in patients with rheumatoid arthritis
• The diffuse alveolar hemorrhage syndromes
• Treatment of essential mixed cryoglobulinemia

Rapidly progressive glomerulonephritis

• Acute glomerulonephritis and pulmonary hemorrhage
• Clinical manifestations and diagnosis of Wegener's granulomatosis and microscopic polyangiitis
• Initial immunosuppressive therapy in Wegener's granulomatosis and microscopic polyangiitis
• Mechanisms of glomerular crescent formation
• Mechanisms of immune injury of the glomerulus
• Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis
• Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease
• Pathogenesis of tissue injury in glomerulonephritis
• Renal disease in infective endocarditis
• Renal manifestations of systemic vasculitis
• The diffuse alveolar hemorrhage syndromes
• Treatment of anti-GBM antibody (Goodpasture's) disease

Treatment

• Alternative agents in the treatment of Wegener's granulomatosis and microscopic polyangiitis
• Complications of therapeutic plasma exchange
• Determinants of glucocorticoid dosing
• General principles of the use of cyclophosphamide in rheumatic and renal disease
• General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases
• Glucocorticoid withdrawal
• Initial immunosuppressive therapy in Wegener's granulomatosis and microscopic polyangiitis
• Major side effects of systemic glucocorticoids
• Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis
• Prescription and technique of therapeutic plasma exchange
• Therapy of diffuse or focal proliferative lupus nephritis
• Treatment and prognosis of IgA nephropathy
• Treatment of anti-GBM antibody (Goodpasture's) disease
• Treatment of cyclophosphamide-resistant Wegener's granulomatosis and microscopic polyangiitis
• Treatment of diabetic nephropathy
• Treatment of essential mixed cryoglobulinemia
• Treatment of membranoproliferative glomerulonephritis type I and type III
• Treatment of minimal change disease in adults
• Treatment of secondary (AA) amyloidosis